ImageneBio, Inc.: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 12, 2021 and accepted by EDGAR at Aug 12, 2021, 16:21 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-01 to 2021-06-30 | $3.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2021-01-01 to 2021-06-30 | $7.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2021-04-01 to 2021-06-30 | $11.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-01-01 to 2021-06-30 | $21.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | −$12.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | −$22.4m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2021-04-01 to 2021-06-30 | −$12.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | −$22.4m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | −$28.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-06-30 | $1.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-06-30 | $264.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $268.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $278.8m | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $30.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $62.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-06-30 | $216.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-21-043997. Last ingested by Listed: Nov 14, 2026, 21:13 ET. Listed shows no prices and gives no investment advice.